GlassScriptPhysician profile
Anh Khoa Pham
NPI 1932582467
$4,534.79
in general payments reported to CMS, 2019-2025
25 companies · $328 in 2025
The $328 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,432 · 2020: $125 · 2021: $100 · 2022: $36.33 · 2023: $949 · 2024: $1,565 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,726 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,726.38 |
| Education | $115.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $1,311.35 | 2019 | |
| Abbvie INC. | $704.66 | 2022-2025 | |
| Janssen Biotech, INC. | $448.94 | 2020-2025 | Tremfya, Simponi Aria, Simponi |
| Regeneron Healthcare Solutions, INC. | $283.38 | 2023-2024 | Dupixent |
| Ucb, INC. | $236.19 | 2023-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $231.51 | 2023-2025 | Nemluvio, Aklief, Epsolay |
| Arcutis Biotherapeutics, INC. | $167.30 | 2023-2024 | Zoryve |
| Incyte Corporation | $149.47 | 2023-2025 | Opzelura |
| Biofrontera INC. | $117.43 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Pfizer INC. | $106.41 | 2023-2025 | |
| Amgen INC. | $93.94 | 2023-2024 | Otezla, Enbrel |
| Genzyme Corporation | $91.74 | 2023-2024 | |
| Organogenesis INC. | $90.55 | 2019 | |
| Sun Pharmaceutical Industries INC. | $73.06 | 2023-2024 | Ilumya, Blu-U, Odomzo |
| Sanofi-Aventis U.S. LLC | $72.00 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $71.61 | 2023-2024 | Adbry |
| Dermavant Sciences, INC. | $65.21 | 2022-2024 | Vtama |
| Merck Sharp & Dohme LLC | $51.48 | 2023-2024 | Keytruda |
| E.R. Squibb & Sons, L.L.C. | $33.42 | 2024 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $30.00 | 2019 | |
| Boston Scientific Corporation | $28.11 | 2021 | |
| Organon LLC | $24.87 | 2025 | Vtama |
| Lilly USA, LLC | $24.82 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $14.05 | 2023 | Valchlor |
| Strata Skin Sciences, INC. | $13.29 | 2023 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anh Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.